MX2020011049A - Oxadiazolopirazinas y oxadiazolopiridinas útiles como desacopladores mitocondriales. - Google Patents

Oxadiazolopirazinas y oxadiazolopiridinas útiles como desacopladores mitocondriales.

Info

Publication number
MX2020011049A
MX2020011049A MX2020011049A MX2020011049A MX2020011049A MX 2020011049 A MX2020011049 A MX 2020011049A MX 2020011049 A MX2020011049 A MX 2020011049A MX 2020011049 A MX2020011049 A MX 2020011049A MX 2020011049 A MX2020011049 A MX 2020011049A
Authority
MX
Mexico
Prior art keywords
formula
compounds
useful
mitochondrial
salts
Prior art date
Application number
MX2020011049A
Other languages
English (en)
Spanish (es)
Inventor
Webster L Santos
Joseph Michael Salamoun
Christopher J Garcia
Jacob H Murray
Original Assignee
Virginia Tech Intellectual Properties Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Tech Intellectual Properties Inc filed Critical Virginia Tech Intellectual Properties Inc
Publication of MX2020011049A publication Critical patent/MX2020011049A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/73—Unsubstituted amino or imino radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/16—Halogen atoms; Nitro radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00—Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02—Boron compounds
    • C07F5/025—Boronic and borinic acid compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)
MX2020011049A 2018-04-20 2019-04-22 Oxadiazolopirazinas y oxadiazolopiridinas útiles como desacopladores mitocondriales. MX2020011049A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862660880P 2018-04-20 2018-04-20
PCT/US2019/028544 WO2019204813A1 (en) 2018-04-20 2019-04-22 Oxadiazolopyrazines and oxadiazolopyridines useful as mitochondrial uncouplers

Publications (1)

Publication Number Publication Date
MX2020011049A true MX2020011049A (es) 2021-01-08

Family

ID=67139787

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020011049A MX2020011049A (es) 2018-04-20 2019-04-22 Oxadiazolopirazinas y oxadiazolopiridinas útiles como desacopladores mitocondriales.
MX2020011050A MX2020011050A (es) 2018-04-20 2019-04-22 Imidazopiridinas útiles como desacopladores mitocondriales.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2020011050A MX2020011050A (es) 2018-04-20 2019-04-22 Imidazopiridinas útiles como desacopladores mitocondriales.

Country Status (12)

Country Link
US (3) US20210253538A1 (enExample)
EP (4) EP3781567B1 (enExample)
JP (3) JP2021523933A (enExample)
KR (3) KR20210003831A (enExample)
CN (3) CN112262146A (enExample)
AU (2) AU2019256722A1 (enExample)
BR (2) BR112020021466A2 (enExample)
CA (2) CA3097752A1 (enExample)
IL (2) IL278069A (enExample)
MX (2) MX2020011049A (enExample)
WO (3) WO2019204813A1 (enExample)
ZA (2) ZA202006296B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3781567B1 (en) 2018-04-20 2022-08-24 Virginia Tech Intellectual Properties, Inc. Imidazopyridines useful as mitochondrial uncouplers
WO2020191503A1 (en) * 2019-03-27 2020-10-01 Algernon Pharmaceuticals Inc. Methods and uses of bromantane and derivatives thereof for treating lung disease, fatty liver disease, and kidney disorders
EP4178955A1 (en) 2020-07-11 2023-05-17 Pfizer Inc. Antiviral heteroaryl ketone derivatives
US11351149B2 (en) 2020-09-03 2022-06-07 Pfizer Inc. Nitrile-containing antiviral compounds
EP4482494A4 (en) * 2022-02-21 2026-02-25 Univ Colorado Regents RE-SENSITIZATION OF MULTI-DRUG-RESISTANT GRAM-NEGATIVE (MDR) BACTERIA TO COLISTIN USING IONOPHORES

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2501680A1 (fr) 1981-03-12 1982-09-17 Elf Aquitaine Synthese de tetra mercaptides stanniques
US4472840A (en) 1981-09-21 1984-09-25 Jefferies Steven R Method of inducing osseous formation by implanting bone graft material
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US5606019A (en) 1987-10-29 1997-02-25 Protien Polymer Technologies, Inc. Synthetic protein as implantables
JP2668259B2 (ja) * 1988-02-18 1997-10-27 塩野義製薬株式会社 複素環化合物および抗潰瘍剤
GB2215209B (en) 1988-03-14 1992-08-26 Osmed Inc Method and apparatus for biodegradable, osteogenic, bone graft substitute device
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
JPH0327172A (ja) 1989-06-19 1991-02-05 Nissan Chem Ind Ltd 布の漂白方法
US5645591A (en) 1990-05-29 1997-07-08 Stryker Corporation Synthetic bone matrix
JPH0741461A (ja) * 1993-05-27 1995-02-10 Eisai Co Ltd スルホン酸エステル誘導体
WO2000052001A1 (en) * 1999-03-03 2000-09-08 Samjin Pharmaceutical Co., Ltd. Piperazine derivatives and process for the preparation thereof
ATE307121T1 (de) * 2000-02-16 2005-11-15 Neurogen Corp Substituierte arylpyrazine
US6777446B2 (en) * 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators
WO2004007472A1 (ja) * 2002-07-10 2004-01-22 Ono Pharmaceutical Co., Ltd. Ｃｃｒ４アンタゴニストおよびその医薬用途
EP1529531A1 (en) 2003-11-04 2005-05-11 4Sc Ag Oxadiazolopyrazine derivatives as pharmaceutically active compounds
WO2005044270A1 (en) 2003-11-04 2005-05-19 4Sc Ag Oxadiazolopyrazine derivatives as pharmaceutically active compounds
JP2008515979A (ja) * 2004-10-14 2008-05-15 コンパス ファーマシューティカルズ リミティド ライアビリティ カンパニー フラザノ‘３，４−ビピラジン（ｂｉｐｙｒａｚｉｎｅ）及び抗腫瘍剤としてのその使用
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
ES2270715B1 (es) 2005-07-29 2008-04-01 Laboratorios Almirall S.A. Nuevos derivados de pirazina.
ES2412007T3 (es) * 2005-12-21 2013-07-09 Janssen Pharmaceutica, N.V. Derivados de pirazinona sustituida novedosos para uso en enfermedades mediadas por MCH-1
EP2017277A1 (en) 2007-06-29 2009-01-21 4Sc Ag Thiophene-imidazopyridines
AU2008345225A1 (en) 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
PL2424530T3 (pl) * 2009-04-30 2016-07-29 Univ Midwestern Sposób i kompozycja do leczenia cukrzycowej kwasicy ketonowej
WO2012020742A1 (ja) * 2010-08-10 2012-02-16 塩野義製薬株式会社 新規複素環誘導体およびそれらを含有する医薬組成物
KR20140077963A (ko) * 2011-10-20 2014-06-24 글락소스미스클라인 엘엘씨 시르투인 조절제로서의 치환된 비시클릭 아자-헤테로사이클 및 유사체
KR101481952B1 (ko) * 2012-04-13 2015-01-22 한국과학기술연구원 신경보호제로서의 유레아 유도체
US9492448B2 (en) 2012-06-20 2016-11-15 University Of Virginia Patent Foundation Compositions and methods for regulating glucose homeostasis and insulin action
TW201441203A (zh) 2012-11-05 2014-11-01 Medeia Therapeutics Ltd Ｎ－取代４－胺苯酚及對應醌亞胺
WO2015000715A1 (en) * 2013-07-02 2015-01-08 Syngenta Participations Ag Pesticidally active bi- or tricyclic heterocycles with sulfur containing substituents
KR101428622B1 (ko) 2014-01-07 2014-08-13 국방과학연구소 옥사디아졸로 피라진기를 포함하는 화합물 또는 염을 포함하는 리튬 이차 전지용 전극 및 이를 포함하는 리튬 이차 전지
CN107108521A (zh) * 2014-10-28 2017-08-29 盐野义制药株式会社 具有ampk活化作用的杂环衍生物
HK1243636A1 (zh) 2014-11-18 2018-07-20 Rutgers, The State University Of New Jersey 用於治疗代谢疾病和癌症的新的线粒体解偶联剂
WO2017151063A1 (en) 2016-03-03 2017-09-08 Agency For Science, Technology And Research Use of furazano[3,4-b]pyrazine derivatives for chemotherapy
TWI754702B (zh) * 2016-12-28 2022-02-11 德商Ｕｃｂ製藥有限公司 （氮雜）吲哚－和苯並呋喃－３－磺醯胺類
EP3630115B1 (en) 2017-05-22 2025-12-10 University Of Virginia Patent Foundation Compositions and methods for preparing and using mitochondrial uncouplers
EP3781567B1 (en) * 2018-04-20 2022-08-24 Virginia Tech Intellectual Properties, Inc. Imidazopyridines useful as mitochondrial uncouplers

Also Published As

Publication number Publication date
CN112261941A (zh) 2021-01-22
BR112020021469A2 (pt) 2021-01-19
US20210238181A1 (en) 2021-08-05
JP2021523933A (ja) 2021-09-09
US20210253538A1 (en) 2021-08-19
AU2019256722A1 (en) 2020-11-05
KR20210009321A (ko) 2021-01-26
JP2021523934A (ja) 2021-09-09
AU2019256719A1 (en) 2020-11-05
CN112262141A (zh) 2021-01-22
ZA202006296B (en) 2023-03-29
EP3781572B1 (en) 2026-06-03
IL278069A (en) 2020-11-30
BR112020021466A2 (pt) 2021-01-19
KR20210003831A (ko) 2021-01-12
EP3781165A1 (en) 2021-02-24
US11708376B2 (en) 2023-07-25
KR102913366B1 (ko) 2026-01-14
CN112262146A (zh) 2021-01-22
EP4763834A3 (en) 2026-08-12
WO2019204813A1 (en) 2019-10-24
WO2019204819A1 (en) 2019-10-24
EP3781567A1 (en) 2021-02-24
MX2020011050A (es) 2021-03-09
CA3097752A1 (en) 2019-10-24
EP3781572A1 (en) 2021-02-24
EP3781567B1 (en) 2022-08-24
KR20210011928A (ko) 2021-02-02
US12655156B2 (en) 2026-06-16
US20210253594A1 (en) 2021-08-19
EP3781165A4 (en) 2022-02-23
CA3097751A1 (en) 2019-10-24
WO2019204816A1 (en) 2019-10-24
JP2021522327A (ja) 2021-08-30
EP4763834A2 (en) 2026-06-24
KR102900692B1 (ko) 2025-12-15
IL278070A (en) 2020-11-30
ZA202006295B (en) 2023-03-29

Similar Documents

Publication Publication Date Title
MX2020011050A (es) Imidazopiridinas útiles como desacopladores mitocondriales.
ECSP21080535A (es) Compuestos y métodos para el tratamiento de covid-19
CY1120974T1 (el) Ετεροκυκλικες ενωσεις, φαρμακα που περιεχουν τις αναφερομενες ενωσεις, χρηση αυτων και διαδικασιες για την παραγωγη τους
PE20180523A1 (es) Compuestos co-agonistas del glucacon y peptido-1 similar al glugacon (glp-1)
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
GEP20217265B (en) Glp-1 receptor agonists and uses thereof
MX2018014016A (es) Polipéptidos selectivos del receptor de glucagón y métodos para utilizarlos.
CO2019009423A2 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos
CL2019001714A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer.
CY1117776T1 (el) Εναντιομερη ενωσεων σπειρο-οξινδολιου και οι χρησεις τους ως θεραπευτικοι παραγοντες
BR112012024379A2 (pt) "peptídeos glucagon, seu uso, bem como composição farmacêutica"
AR100560A1 (es) Inhibición o regulación por disminución de la glucógeno sintasa mediante la creación de codones de terminación prematuros utilizando oligonucléotidos antisentido
CU20140035A7 (es) Proteínas de función dual para tratar trastornos metabólicos
CU20130073A7 (es) Péptidos derivados del factor de crecimiento de fibroblastos 21 ( fgf21) útiles como reguladores metabólicos
UY32240A (es) Nuevas 2,4-diaminopirimidinas, sus sales farmacéuticamente aceptables, composiciones conteniéndolas y aplicaciones.
MX382630B (es) Compuestos de pirazol disustituidos para el tratamiento de enfermedades.
AR105319A1 (es) Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
MX2017003780A (es) Composicion farmaceutica para tratar colitis ulcerativa.
EA201891007A1 (ru) Нацеливание на формилпептидный рецептор 2/рецептор липоксина a(fpr2/alx) для лечения заболеваний сердца
MX389553B (es) Composicion para incrementar la expresion de pgc-1alfa
MX2021004185A (es) Polipeptidos analogos de la amilina humana y sus metodos de uso.
PE20180247A1 (es) Derivados de pirazol utiles como inhibidores de proteina activadora de 5-lipoxigenasa (flap)
MX2023012851A (es) Métodos de tratamiento y seguimiento de la enfermedad de parkinson.
JP2018517767A5 (enExample)
UY33568A (es) Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes.